![Ellen Donnelly](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ellen Donnelly
Amministratore Delegato presso ABLIVA AB
Posizioni attive di Ellen Donnelly
Società | Posizione | Inizio | Fine |
---|---|---|---|
ALZECURE PHARMA AB | Direttore/Membro del Consiglio | 01/01/2018 | - |
Independent Dir/Board Member | 01/01/2018 | - | |
MODUS THERAPEUTICS HOLDING AB | Direttore/Membro del Consiglio | 01/01/2020 | - |
Independent Dir/Board Member | 01/01/2020 | - | |
Amministratore Delegato | - | 01/01/2020 | |
ABLIVA AB | Amministratore Delegato | 03/02/2021 | - |
Modus Therapeutics AB
![]() Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Direttore/Membro del Consiglio | 01/01/2019 | - |
Amministratore Delegato | 01/01/2016 | 01/01/2019 |
Storia della carriera di Ellen Donnelly
Precedenti posizioni note di Ellen Donnelly
Società | Posizione | Inizio | Fine |
---|---|---|---|
Souvien Therapeutics | Amministratore Delegato | - | - |
Juvenescence Ltd.
![]() Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Corporate Officer/Principal | - | - |
Formazione di Ellen Donnelly
Yale School of Medicine | Doctorate Degree |
Statistiche
Distribuzione geografica
Svezia | 5 |
Stati Uniti | 3 |
Regno Unito | 2 |
Posizioni
Chief Executive Officer | 4 |
Director/Board Member | 3 |
Independent Dir/Board Member | 2 |
Settori
Health Technology | 5 |
Finance | 2 |
Consumer Services | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
ALZECURE PHARMA AB | Health Technology |
MODUS THERAPEUTICS HOLDING AB | Health Technology |
ABLIVA AB | Health Technology |
Aziende private | 3 |
---|---|
Modus Therapeutics AB
![]() Modus Therapeutics AB Pharmaceuticals: MajorHealth Technology Modus Therapeutics AB operates as a clinical-stage drug development company that develops new pharmaceutical therapies designed to restore impaired blood flow and oxygen transport in diseases with unmet medical needs. The firm’s product Sevuparin, evaluates in a phase II clinical trial in sickle cell disease (SCD) and repeated painful crises in SCD, so called vaso-occlusive crises (VOC) that leads to loss of vital organ function and reduced life span. The company was founded by Carl Mats Wahlgren in 2011 and is headquartered in Solna, Sweden. | Health Technology |
Juvenescence Ltd.
![]() Juvenescence Ltd. Financial ConglomeratesFinance Juvenescence Ltd. engages in operation as an investment holding company which develops therapeutic products for human ageing and longevity. It provides drug development, new company creation, academic licensing, and biotech investment. The company was founded by James Mellon, Gregory H. Bailey, Declan Dooganin, Alexander Pickett, and Anthony Chow in October 2016 and is headquartered in Liverpool, the United Kingdom. | Finance |
Souvien Therapeutics |
- Borsa valori
- Insiders
- Ellen Donnelly
- Esperienza